Chimeric Therapeutics Issues New Shares Under Corporations Act Disclosure Exemption

Chimeric Therapeutics Ltd. ( (AU:CHM) ) has shared an update.

Chimeric Therapeutics has issued 6,900,993 new ordinary shares on 4 May 2026 under ASX code CHM without a prospectus, relying on provisions of the Corporations Act that allow certain placements without full disclosure. The company confirmed it is compliant with its continuous disclosure and reporting obligations and stated there is no undisclosed excluded information, signalling that the capital raising is being conducted within the standard regulatory framework and without hidden material risks for investors.

The notice reassures the market that Chimeric remains up to date with statutory reporting and disclosure rules, which is important for maintaining investor confidence as the share base expands. By affirming there is no additional material information requiring disclosure, the company aims to reduce uncertainty around the new share issuance and its potential impact on existing shareholders and market perception.

More about Chimeric Therapeutics Ltd.

Chimeric Therapeutics Ltd. is an Australian biotechnology company listed on the ASX under the ticker CHM. The company operates in the life sciences sector, focusing on developing advanced therapeutic products, and raises capital through ordinary share issuances to support its research and corporate activities.

Average Trading Volume: 220,497

Technical Sentiment Signal: Sell

Current Market Cap: A$7.29M

See more data about CHM stock on TipRanks’ Stock Analysis page.